Treatment of an Nb-Pr-A.I.-3 (autonomous) Tumor with Combination Chemotherapy

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1981 Jan 1

PMID 7197592

Authors

J R Drago

T Worgul

Affiliations

Soon will be listed here.

Abstract

The rat prostatic adenocarcinoma Nb-Pr-A.I.-3, an androgen-insensitive tumor, was evaluated with the following treatments: cyclophosphamide, cis-platinum, adriamycin, and the following combination therapies: cyclophosphamide and cis-platinum; adriamycin and cis-platinum; adriamycin, cis-platinum, and cyclophosphamide. Successful therapeutic combinations included cyclophosphamide alone (P Less Than 0.001) and the triple-drug combination (P Less Than 0.001). Significance was based on the final tumor volume at the termination of the experiment. Cyclophosphamide treatment alone was the only therapeutic regimen that resulted in complete tumor regression (16%) (2/12). Cyclophosphamide therapy also resulted in the lowest number of animals with metastasis (25%). On the basis of this study, the authors rate this animal model as a suitable one for trials of various chemotherapeutic combinations as well as for determining combination or single agents useful in preducing tumor regression and a decreased number of metastasis.

References

NOBLE R . The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977; 37(6):1929-33. View

Drago J, Ikeda R, MAURER R, GOLDMAN L, Tesluk H . The Nb rat: prostatic adenocarcinoma model. Invest Urol. 1979; 16(5):353-9. View

WHITMORE Jr W . Proceedings: The natural history of prostatic cancer. Cancer. 1973; 32(5):1104-12. DOI: 10.1002/1097-0142(197311)32:5<1104::aid-cncr2820320515>3.0.co;2-t. View

Drago J, Gershwin M, MAURER R, Ikeda R, Eckels D . Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostate adenocarcinoma into congenitally athymic (nude) mice. I. Hormone dependency and histopathology. J Natl Cancer Inst. 1979; 62(4):1057-66. View

Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G . Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J Urol. 1976; 115(1):86-8. DOI: 10.1016/s0022-5347(17)59077-1. View

Scott W, Johnson D, Schmidt J, Gibbons R, Prout G, Joiner J . Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. J Urol. 1975; 114(6):909-11. DOI: 10.1016/s0022-5347(17)67172-6. View

Eagan R, Hahn R, Myers R . Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep. 1976; 60(1):115-7. View

NOBLE R . Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res. 1977; 37(1):82-94. View

Carter S, Wasserman T . The chemotherapy of urologic cancer. Cancer. 1975; 36(2):729-47. DOI: 10.1002/1097-0142(197508)36:2+<729::aid-cncr2820360818>3.0.co;2-d. View

10.

. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet. 1967; 124(5):1011-7. View

11.

Drago J, MAURER R, GOLDMAN L, Gershwin M . Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostatic adenocarcinoma. Chemotherapy of autonomous tumor, 102 Pr, heterotransplanted into congenitally athymic (nude) mice and syngeneic Nb rats. Cancer Chemother Pharmacol. 1979; 3(3):167-70. DOI: 10.1007/BF00262417. View

12.

Drago J, GOLDMAN L, MAURER R, Gershwin M, Eckels D . Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors. Invest Urol. 1979; 17(3):203-6. View